Overview

Beta Blockers In Acute Ischemic Stroke

Status:
Completed
Trial end date:
2013-04-01
Target enrollment:
0
Participant gender:
All
Summary
The objective of this trial is to assess the safety and efficacy of neuro- and cardioprotective effects of propranolol in acute ischemic stroke. Furthermore, exploratory analyses of cardiologic-electrophysiologic and immunologic parameters will be performed.
Phase:
Phase 2/Phase 3
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Wilhelm Haverkamp
Collaborator:
German Federal Ministry of Education and Research
Treatments:
Adrenergic beta-Antagonists
Propranolol
Criteria
Inclusion Criteria:

- Symptom onset within 18 hours

- Acute ischemic MCA-territory stroke

- Patients with suspected stroke in MCA-territory and a) NIHSS > 3 or b) imaging
evidence of MCA-infarction

Exclusion Criteria:

- Patients already receiving beta-blockers

- Anti-arrhythmic, antiinfectious, antiinflammatory or immunosuppressive therapy

- Patients with a major heart disease, hypotension, bradycardia or any contraindication
to the use of Propranolol